Bortecad 2 mg Injection
  1. Home
  2. Pharma Products
  3. Cadila Pharmaceutical Ltd
  4. Bortecad 2 mg Injection

Bortecad 2 mg Injection

Bortecad 2 mg Injection contains bortezomib, an anti-cancer medicine used mainly for multiple myeloma and mantle-cell lymphoma. It is administered by a qualified healthcare professional through intravenous or subcutaneous injection. Bortezomib works by blocking proteasomes in cancer cells, which can lead to cancer-cell death.

BUY NOW

Category

Bortecad 2 mg Injection is a proteasome inhibitor used as part of specific treatment regimens for multiple myeloma and mantle-cell lymphoma. By interfering with the normal breakdown of proteins inside cancer cells, bortezomib causes accumulation of abnormal proteins and promotes cancer-cell death. The dose and treatment schedule are determined by the oncologist according to the patient’s condition and treatment protocol. Blood counts and other clinical parameters may be monitored during therapy.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 2 mg
Dosage Form Powder for Injection
Route of Administration Intravenous or Subcutaneous
Pack Size 1 Vial
Manufacturer Cadila Pharmaceuticals Ltd

Product Also Known As

Bortecad 2 mg Injection, Bortecad 2 mg Inj, Bortecad Bortezomib Injection, Bortezomib 2 mg Injection, Bortezomib Oncology Injection, Bortezomib Anti-Cancer Injection